Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half

Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half

This post was originally published on this siteBiogen is slashing the price of its controversial new Alzheimer’s disease treatment Aduhelm in half in a bid to revive a product launch that has stalled in part because of a backlash over the drug’s cost.

Read more